论文部分内容阅读
乳腺癌术后辅助化疗的时机选择问题,相关研究层出不穷并仍在继续,但目前为止尚无定论。术后辅助化疗的时机对患者的生存有影响,早期乳腺癌患者辅助化疗时机超过12周与患者较差的生存相关,早期快速增殖型乳腺癌辅助化疗时机在7周内将使患者生存获益。III期、三阴性以及HER-2阳性且接受曲妥珠单克隆抗体治疗等高危乳腺癌患者,术后辅助化疗时机超过61天对生存结局造成不利影响。对于术后的辅助化疗总体来说,在患者状况允许的前提下,尽快制定化疗方案,尽早化疗,避免延迟。
The timing of postoperative adjuvant chemotherapy for breast cancer is a matter of choice, and the research is endless and continuing, but so far it is inconclusive. The timing of postoperative adjuvant chemotherapy has an impact on patient survival. The timing of adjuvant chemotherapy in patients with early-stage breast cancer over 12 weeks is associated with poor survival in patients, and the timing of adjuvant chemotherapy for early-stage proliferative breast cancer is expected to benefit the patient’s survival within 7 weeks . Stage III, triple negative and HER-2-positive patients receiving high-risk breast cancer such as trastuzumab therapy have an adverse effect on survival after more than 61 days of adjuvant chemotherapy. For postoperative adjuvant chemotherapy in general, under the premise of the patient’s condition, the development of chemotherapy as soon as possible, as soon as possible chemotherapy, to avoid delay.